Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Post-Market Studies May Be "Least Burdensome" Alternative - Industry

This article was originally published in The Gray Sheet

Executive Summary

FDA should consider postmarket controls for breakthrough devices as an alternative to randomized, controlled clinical studies as a "least burdensome" route to approval, a pan-industry task force suggests in Nov. 24 comments on FDA's draft guidance.

You may also be interested in...



Least Burdensome Draft Guidance Would Unduly Increase RCTs - Medtronic

FDA's draft guidance on least burdensome premarket requirements likely would increase above current levels the frequency at which randomized controlled trials (RCTs) are required to support premarket approval, leading to "significant over regulation," Medtronic maintains in comments to FDA.

Least Burdensome Draft Guidance Would Unduly Increase RCTs - Medtronic

FDA's draft guidance on least burdensome premarket requirements likely would increase above current levels the frequency at which randomized controlled trials (RCTs) are required to support premarket approval, leading to "significant over regulation," Medtronic maintains in comments to FDA.

FDA "Least Burdensome" Draft Guidance Unhelpful, Medical Alley Says

FDA's recently released "least burdensome" draft guidance is not a useful tool for manufacturers seeking regulatory approvals, Medical Alley contends in comments submitted to the agency Nov. 23.

Related Content

UsernamePublicRestriction

Register

MT012680

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel